Advertisement

Chromatographia

, Volume 78, Issue 7–8, pp 579–583 | Cite as

HPLC Determination of Enantiomeric Purity of PF-04136309 Based on a Chiral Stationary Phase

  • Zeping Zuo
  • Mingxing Hu
  • Miaomiao Chen
  • Xiuli Chen
  • Fangfang Yang
  • Chenjuan Zeng
  • Yinglan ZhaoEmail author
  • Yiwen ZhangEmail author
Short Communication

Abstract

A precise and sensitive LC method was developed and further validated for the determination of enantiomeric purity of (S)-N-[2-(3-{trans-4-hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl] cyclohexylamino} pyrrolidin-1-yl)-2-oxoethyl]-3-(trifluoromethyl) benzamide (PF-04136309). Baseline separation with a resolution higher than 1.8 was accomplished within 40 min using a CHIRALPAK AD (250 × 4.6 mm; particle size 5 μm) column, with n-hexane:2-propanol (70:30 v/v) as mobile phase at a flow rate of 1 mL min−1. The eluted analytes were subsequently detected with a UV detector at 260 nm. The effects of mobile phase components and temperature on enantiomeric selectivity as well as the resolution of enantiomers were thoroughly investigated. The calibration curves were plotted within a concentration range between 0.01 and 1 mg mL−1 (n = 9), and recoveries between 98.17 and 101.28 % were obtained, with relative standard deviation (RSD) lower than 1.44 %. The LOD and LOQ for PF-04136309 were 3.59 and 11.54 μg mL−1 and for its enantiomer were 3.39 and 11.28 μg mL−1, respectively. The developed method was demonstrated to be accurate, robust and sensitive for the determination of enantiomeric purity of PF-04136309, especially for the analysis of bulk samples.

Keywords

Column liquid chromatography Chiral separation Enantiomeric purity PF-04136309 

References

  1. 1.
    Xue CB, Wang A, Han Q, Zhang Y, Cao G, Feng H, Huang T, Zheng C, Xia M, Zhang K, Kong L, Glenn J, Anand R, Meloni D, Robinson DJ, Shao L, Storace L, Li M, Hughes RO, Devraj R, Morton PA, Joseph Rogier D, Covington M, Scherle P, Diamond S, Emm T, Yeleswaram S, Contel N, Vaddi K, Newton R, Hollis G, Metcaif B (2011) ACS Med Chem Lett 2:913–918CrossRefGoogle Scholar
  2. 2.
    Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester G (2000) Arthritis Res 2:189–202CrossRefGoogle Scholar
  3. 3.
    Feria M, Diaz-Conzalez F (2006) Expert Opin Ther Pat 16:49–57CrossRefGoogle Scholar
  4. 4.
    Xia M, Sui Z (2009) Expert Opin Ther Pat 19:295–303CrossRefGoogle Scholar
  5. 5.
    Pease JE, Horuk R (2009) Expert Opin Ther Pat 19:39–58CrossRefGoogle Scholar
  6. 6.
    Struthers M, Pasternak A (2010) Curr Top Med Chem 10:1278–1298CrossRefGoogle Scholar
  7. 7.
    Pasternak A, Goble SD, Struthers M, Vicario PP, Ayala JM, Di Salvo J, Kilburn R, Wisniewski T, DeMartino JA, Mills SG, Yang L (2010) ACS Med Chem Lett 1:14–18CrossRefGoogle Scholar
  8. 9.
    Peace S, Philp J, Brooks C, Piercy V, Moores K, Smethurst C, Watson S, Gaines S, Zippoli M, Mookherjee C, Ife R (2010) Bioorg Med Chem Lett 20:3961–3964CrossRefGoogle Scholar
  9. 10.
    Xue CB, Wang A, Meloni D, Zhang K, Kong L, Feng H, Glenn J, Huang T, Zhang Y, Cao G, Anand R, Zheng C, Xia M, Han Q, Robinson DJ, Storace L, Shao L, Li M, Brodmerkel CM, Covington M, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B (2010) Bioorg Med Chem Lett 20:7473–7478CrossRefGoogle Scholar
  10. 11.
    Zheng C, Cao G, Xia M, Feng H, Glenn J, Anand R, Zhang K, Huang T, Wang A, Kong L, Li M, Galya L, Hughes RO, Devraj R, Morton PA, Rogier DJ, Covington M, Baribaud F, Shin N, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B, Xue CB (2011) Bioorg Med Chem Lett 21:1442–1446CrossRefGoogle Scholar
  11. 12.
    Xue CB, Feng H, Cao G, Huang T, Glenn J, Anand R, Meloni D, Zhang K, Kong L, Wang A, Zhang Y, Zheng C, Xia M, Chen L, Tanaka H, Han Q, Robinson DJ, Modi D, Storace L, Shao L, Sharief V, Li M, Covington M, Scherle P, Diamond S, Emm T, Yeleswaram S, Contel N, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B (2011) ACS Med Chem Lett 2:450–454CrossRefGoogle Scholar
  12. 13.
    Tang XH, Yang D, Xie YM, Cao Y, Song H (2009) Chromatographia 70:365–369CrossRefGoogle Scholar
  13. 14.
    Xie YM, Luo J, Tang XH, Yang D, Huo XF, Liu A, Hu X, Song X, Song H (2009) Chromatographia 69:1025–1029CrossRefGoogle Scholar
  14. 15.
    Rane VP, Pati KR, Sangshetti JN, Shinde DB (2008) Chromatographia 67:777–781CrossRefGoogle Scholar
  15. 16.
    Xue CB, Metcalf B, Han AQ, Robinson DJ, Zheng C, Wang A, Zhang Y (2005) PCT Int Appl: WO 2005060665 A2Google Scholar
  16. 17.
    Burgess G (2012) PCT Int Appl: WO 2012114223 A1Google Scholar
  17. 18.
    Sun Q, Olesik SV (2000) J Chromatogr B 745:159–166CrossRefGoogle Scholar
  18. 19.
    Ding GS, Liu Y, Cong RZ, Wang JD (2004) Talanta 62:997–1003CrossRefGoogle Scholar
  19. 20.
    Nageswara Rao R, Narasa Raju A, Nagaraju D (2006) J Pharm Biomed Anal 42:347–353CrossRefGoogle Scholar
  20. 21.
    Berthod A, Li W, Armstrong DW (1992) Anal Chem 64:873–879CrossRefGoogle Scholar
  21. 22.
    Loun B, Hage DS (1994) Anal Chem 66:3814–3822CrossRefGoogle Scholar
  22. 23.
    Stringham RW, Blackwell JA (1997) Anal Chem 69:1414–1420CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Zeping Zuo
    • 1
  • Mingxing Hu
    • 1
  • Miaomiao Chen
    • 1
  • Xiuli Chen
    • 1
  • Fangfang Yang
    • 1
  • Chenjuan Zeng
    • 2
  • Yinglan Zhao
    • 1
    Email author
  • Yiwen Zhang
    • 1
    Email author
  1. 1.State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, West China Medical SchoolSichuan UniversityChengduChina
  2. 2.Sichuan Gooddoctor Panxi Pharmaceutical Co., Ltd.ChengduChina

Personalised recommendations